Oncology: Follicular and Mantle Cell Lymphoma (Audio-Digest Foundation Oncology Continuing Medical Education (CME). Book 3)

Purpose: Audio-Digest Foundation CME/CE activities are designed to provide its learners – physicians and other healthcare professionals – with continuing education that will help identify clinical problems in their practice settings, provide content to help to solve those problems, and increase their application of knowledge to practice.

Audio-Digest Oncology is specifically designed to provide the participant with up-to-date and accurate information on areas of competency as identified by the ABIM Medical Oncology MOC Examination Blueprint and ASCO's Core Curriculum Outline. Topics include, but are not limited to, the following:

The 37 cancer types and sites
Treatment regimens and methods, including chemotherapy, radiation therapy, hormonal therapies, and biological response modifiers
Other treatment-related issues, including oncological emergencies, paraneoplastic syndrome, bone marrow transplantation, local therapy of metastatic cancers, and management of malignant effusions
Complications, including infections and other complications of treatment; effects of disease and treatment on the patient, including psychosocial and psychological issues
Supportive care, including pain management, hematopoietic growth factors, transfusion therapy,nutritional support, end-of-life care, etc.
Procedures, including chemotherapy administrations, tumor assessment, bone marrow aspiration, biopsy and interpretation
Geriatric oncology

The goal of this program is to improve the management of follicular and mantle cell lymphomas. After hearing and assimilating this program, the clinician will be better able to:

1: Recognize the differences between grades of follicular lymphomas (FL) and between FL and mantle cell lymphomas (MCLs).

2: Evaluate the evidence for the use of rituximab in FL.

3: Recognize the role of autologous stem cell transplantation in the treatment of FL.

4: Assess patients with FL and MLC using polymerase chain reaction to determine the presence of minimal residual disease (MRD).

5: Determine the prognosis of patients with FL and MCL using assessment of MRD.